Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Holding CYTK?
Track your performance easily
CYTK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$44.49 - $84.05
Previous CloseN/A
Volume107.14K
Average Volume (3M)1.22M
Market Cap
$5.99B
Enterprise Value$5.99B
Total Cash (Recent Filing)$156.25M
Total Debt (Recent Filing)$27.38M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Feb 20, 2025EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.39
Shares Outstanding118,014,240
10 Day Avg. Volume1,375,309
30 Day Avg. Volume1,220,054
Standard Deviation0.24
R-Squared0.03
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1860.58
Price to Cash Flow (P/CF)-14.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.86K
Enterprise Value/Gross Profit-18.57
Enterprise Value/Ebitda-12.37
Forecast
1Y Price Target
$83.88Price Target Upside72.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Cytokinetics News
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentCytokinetics is advancing additional late-stage cardiovascular drug candidates and programs, showing a diverse development pipeline.
Regulatory ProgressThe expanding body of evidence of SEQUIOA-HCM is strongly supportive of the potential approval of aficamten for the treatment of oHCM.
Strategic InitiativesCytokinetics unveiled its 'Vision 2030' 5-year strategic roadmap and highlighted top priorities for 2025 which could drive meaningful near- and long-term value for the company.
Bears Say
Acquisition ExpectationsShares may face some near-term pressure on the news as it suggests no imminent acquisition, which has been a key focus amongst investors.
Market PerformanceDespite recent recovery, Cytokinetics' stock remains significantly down year-to-date.
Regulatory ChallengesCYTK shares are expected to be pressured over the lack of an accelerated review given potential negative read-throughs to the drug’s profile.
---
Ownership Overview
0.76% Insiders
37.56% Mutual Funds
0.14% Other Institutional Investors
38.23% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $44.49 and its highest was $84.05 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $5.99B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Feb 20, 2025 which is in 21 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Nov 06, 2024. The company reported -$1.36 earnings per share for the quarter, missing the consensus estimate of -$1.235 by -$0.125.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.22.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 118,014,240 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.36 in its last earnings report, missing expectations of -$1.235. Following the earnings report the stock price went up 0.613%.
Which hedge fund is a major shareholder of Cytokinetics?
Among the largest hedge funds holding Cytokinetics’s share is Fisher Asset Management LLC. It holds Cytokinetics’s shares valued at 29M.
---
Cytokinetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.88 (72.42% Upside)
$83.88 (72.42% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 58.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.9%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.93%
12-Months-Change
Fundamentals
Return on Equity
4143.50%
Trailing 12-Months
Asset Growth
93.90%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
---
CYTK Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress, particularly with the NDA submissions for aficamten and positive clinical data. Commercial preparations are well underway, backed by a strong financial position. However, increased losses and low revenues remain challenges.Read More>---
CYTK Stock 12 Month Forecast
Average Price Target
$83.88
▲(72.42% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering CYTK
1 Year
1 Year Success Rate
30/47 ratings generated profit
1 Year Average Return
+31.56%
reiterated a buy rating 2 months ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 63.83% of your transactions generating a profit, with an average return of +31.56% per trade.
---